AstraZeneca said on Monday its experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, ...

This optimism is further supported by the company’s strategic decision to resubmit a Biologics License Application for Dato-DXd in EGFR+ NSCLC, backed by promising trial data. These factors ...

AstraZeneca (AZN) Rare Disease, Alexion and Merck (MRK) announced positive topline results from the Phase 3 KOMET trial, a Phase 3 trial in adults with neurofibromatosis type 1 – NF1 – who have ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...

AstraZeneca is gearing up for a mid-stage trial of AZD6234 in combination with its weekly GLP-1/glucagon candidate AZD9550. This once-weekly combo treatment should provide a “triple mechanism ...

AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The Anglo-Swedish drugmaker’s closely watched weight loss pill, AZD5004 ...

(RTTNews) - AstraZeneca plc (AZN, AZN.L) announced on Monday that the high-level results from the TROPION-Breast01 Phase III trial of datopotamab deruxtecan or Dato-DXd compared to the ...

Sharon Barr, executive vice president of biopharmaceuticals R&D, said AstraZeneca had progressed the drug into Phase II clinical trials based on the data from Phase I, which assessed its safety ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial. The Phase I trial, which had 72 participants ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial, with side effects consistent with the GLP-1 drug class.